Silo Pharma awarded U.S. patent for PTSD treatment

Silo Pharma (SILO) announced that the U.S. Patent and Trademark Office issued a Notice of Allowance for patent application 17/954,864 for “Pharmacological Prophylactics Against Stress-Induced Affective Disorders in Females.” Following receipt of the Notice of Allowance, Silo filed the final issue paperwork, paid the issue fees, and expects formal issuance of the patent in the next 90 days The patent, when formally approved, will reinforce protection for Silo’s lead asset, SPC-15, an intranasal treatment targeting post-traumatic stress disorder. The patent includes newly added claims to U.S. Patent 11,491,120, which was issued to Silo in February 2023. Silo holds an exclusive license agreement with Columbia University to further develop, manufacture, and commercialize SPC-15 globally. Through the agreement, Silo acquired extensive issued patents and pending IP patent applications for SPC-15 technology.